Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31545209 | 1.00 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL1740902 | 1.00 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL3460220 | 1.00 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL3486527 | 0.98 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL30861235 | 0.98 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL29542459 | 0.98 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL266899 | 0.86 | HTR2A (0.75) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL29968339 | 0.86 | HTR2A (0.75) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL2556418 | 0.86 | HTR2A (0.75) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL4960829 | 0.85 | HTR2A (0.74) | HTR2ATAAR1ADRA1AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4000197-A | FROM PHENYLACETONES AND METHYL BENZYLAMINE, REDUCTION, HYDROGENOLYSIS | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1976-12-28 | — | — | US | claimed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4673430-A2 | PHENYLALKYLAMINE PRODRUGS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673127-A1 | DEUTERATED AND FLUORINATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI INC (US) | 2025-08-07 | — | — | US | disclosed |
| WO-2010088911-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET A/S (DK) | 2010-08-12 | — | — | WO | disclosed |
| US-20100203130-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| WO-2010089132-A1 | IMMEDIATE RELEASE COMPOSITION RESISTANT TO ABUSE BY INTAKE OF ALCOHOL | EGALET A/S (DK) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010083843-A1 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY | EGALET A/S (DK) | 2010-07-29 | — | — | WO | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080075772-A1 | PHARMACEUTICAL COMPOSITIONS HAVING NOVEL SCORING PATTERNS AND METHODS OF USING THOSE COMPOSITIONS | ACCU-BREAK TECHNOLOGIES, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | CNR2, CNR1, HCN3 | HTR2A 25/4885HTR1A 37/4885HTR2C 6/4885 |
| US-20100203130-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | OPRK1, CES2, OPRM1 | HTR2A 86/4885HTR1A 180/4885HTR2C 74/4885 |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | HTR2A 18/4885HTR1A 29/4885HTR2C 44/4885 |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | PNMT, SLC18A2, SLC1A2 | HTR2A 4/4885HTR1A 5/4885HTR2C 15/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | HTR2A 2491/4885HTR1A 1360/4885HTR2C 1619/4885 |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | MAOA, MAOB, HTR1A | HTR2A 9/4885HTR1A 3/4885HTR2C 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.